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Clostridium diffi  cile infection in children: 
characteristics and treatment 
– a single-center study from Romania
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The incidence of Clostridium diffi  cile infection (CDI) in children is progressively increasing. The study evaluated the characteristics 
and antibacterial treatment of CDI at a Romanian pediatric gastroenterology department. We performed a retrospective study to 
analyze cases diagnosed with CDI, identifi ed through immunoassays for Clostridium diffi  cile toxins in stools, between January 1, 
2005 and December 31, 2015. Eighty-nine episodes of CDI were diagnosed in 73 patients. We noticed an increasing incidence reach-
ing maximum in 2014 with 6.9 cases/1000 patients. Almost 40% of patients had community-acquired CDI. The most frequently 
associated comorbidities were infl ammatory bowel disease and cow’s milk allergy. There was a small percentage of recurrent epi-
sodes (24.2%). Metronidazole was administered as fi rst-line treatment in 49.2% of mild/moderate cases and proved eff ective in 79.4% 
of these. More than 70% of all patients in which metronidazole was not effi  cient had comorbidities, compared to 22.2% of patients 
where metronidazole was effi  cacious. The alternative was vancomycin which cured the disease in all cases. In severe forms, a com-
bination of intravenous metronidazole and oral vancomycin was the effi  cient solution. Oral vancomycin was the effi  cacious treat-
ment for the fi rst recurrence. We report an increasing incidence of CDI in Romanian children. The failure rate for metronidazole 
treatment was low, thus metronidazole may be safely recommended for the fi rst episode of mild/moderate CDI. Vancomycin proved 
eff ective in all cases, regardless of the fi rst episode or recurrence, and may be used effi  ciently as fi rst-line treatment.
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INTRODUCTION
Clostridium diffi  cile is an anaerobe, gram-positive, spore-
forming bacillus which was identifi ed in 1935 in fecal fl ora 
of newborns, but was considered non-pathogenic for a 
long time (1). Years later, in 1978, Bartlett et al. isolated Clos-
tridium diffi  cile and proved it to be the source of cytotoxins 
in the stools of patients with pseudomembranous colitis (2). 
Lately, several studies demonstrated an increase in the inci-
dence of this infection in adults. Although in the past Clos-
tridium diffi  cile infection (CDI) was not considered a prob-
lem in pediatric age, in the last decades several studies have 
been published demonstrating an increasing incidence of 
the disease in children in the USA and Europe (3-5). CDI has 
always been regarded as a nosocomial infection and is in-
deed the second most common hospital-acquired diarrhe-
al disease after rotavirus infection (6). Use of antibiotics and 
prolonged hospital stay are considered risk factors for CDI. 
Associations between CDI and infl ammatory bowel disease, 
immune defi ciencies, Hirschsprung’s disease, cystic fi brosis, 
hematologic malignancies, or organ transplantation have 
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been reported. Several studies have been published dem-
onstrating a signifi cant percentage of community-acquired 
CDI in pediatric patients (7, 8). Therapeutic approach is dif-
fi cult in the severe forms of the disease, especially in pa-
tients with comorbidities or in patients with recurrent CDI.
Just a small number of articles consider epidemiological as-
pects of CDI in Romania (9-11). Still, its incidence has recent-
ly been shown to increase in adult patients (12). We found 
no studies assessing the characteristics of CDI and thera-
peutic approach to pediatric CDI in our country. This study 
aimed to evaluate the characteristics and antibacterial 
treatment of CDI based on the experience of a single Roma-
nian pediatric gastroenterology department.
PATIENTS AND METHODS
This retrospective study analyzed the cases diagnosed with 
CDI and admitted to the Pediatric Gastroenterology Depart-
ment, Grigore Alexandrescu Emergency Children’s Hospital, 
between January 1, 2005 and December 31, 2015. We se-
lected cases identifi ed through enzyme immunoassays for 
Clostridium diffi  cile toxin A in stools between 2005 and 2007, 
and through enzyme immunoassays for Clostridium diffi  cile 
toxins A and B between 2008 and 2015. The tests were ini-
tially performed in a laboratory outside our department and 
since 2014, they have become available in our clinical labo-
ratory.
The following data were extracted from patient medical re-
cords: age, sex, past medical history, clinical manifestations, 
comorbidities, laboratory diagnostic tests, treatment of the 
fi rst episode, recurrence of CDI, and treatment of recurrent 
episodes.
The antibiotic was considered effi  cacious when symptom 
relief and negative Clostridium diffi  cile toxin test result were 
reported after treatment. A second CDI episode occurring 
after successful treatment of a previous, confi rmed by posi-
tive test result, was considered a recurrence.
For statistical analysis, we used Microsoft Excel and SPSS v. 
20. The χ2-test and Fisher test were used to compare cate-
gorical variables. The level of statistical signifi cance was set 
at p<0.05.
The study was approved by the Ethics Committee of the 
Grigore Alexandrescu Emergency Children’s Hospital.
RESULTS
Between January 1, 2005 and December 31, 2015, 589 tests 
were performed in 404 patients. There were 89 episodes of 
CDI in 73 patients admitted to the Pediatric Gastroenterol-
ogy Department, Grigore Alexandrescu Emergency Chil-
dren’s Hospital. The mean incidence of CDI was 2.49 cases 
per 1000 admitted patients. The number of confi rmed cases 
had an increasing tendency, from 0.42 cases/1000 patients 
admitted in 2005, reaching 3.46 cases/1000 patients admit-
ted in 2012, to the maximum of 6.93 in 2014 (Figure 1).
The median age of patients with CDI was 28 months, rang-
ing from fi ve months to 16 years and 8 months. A large 
number of cases (37 patients) were diagnosed in the age 
group one to 4 years (Figure 2).
All patients had diarrhea (liquid stools) and 32 (43.8%) pa-
tients had bloody stools. There were 67 cases of mild to 
moderate forms of CDI and six cases with severe forms, one 
of which was confi rmed to be pseudomembranous colitis, 
confi rmed by colonoscopy. Regarding community-ac-
quired CDI, 28 (38.3%) cases were reported. The characteris-
tics of CDI patients are shown in Table 1.
Thirty-fi ve (47.9%) cases were associated with one or more 
comorbidities (Table 2). Seventeen patients had severe un-
derlying comorbidities (Hirschsprung’s disease, infl amma-
tory bowel disease, cystic fi brosis or intractable diarrhea). 
Six children had immunodefi ciencies, three were diagnosed 
with celiac disease and 13 with food allergies.
FIGURE 1. Incidence of Clostridium diffi  cile infection/1000 patients 
admitted 2005-2015.
FIGURE 2. Distribution of patients with Clostridium diffi  cile infection 
according to age.
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Out of the 73 patients initially included, seven were lost 
from follow up. Complete data on treatment, course of the 
disease and outcome were available for 66 patients. We re-
port 16 cases of recurrent CDI (24.2% of 66 patients). Twelve 
of 16 children with recurrent CDI had comorbidities and 
eight of them had severe underlying medical illnesses 
(three cases with Hirschsprung’s disease and fi ve cases with 
infl ammatory bowel disease), as compared with seven of 57 
patients without recurrences that had severe underlying 
medical illnesses (p=0.0026).
Oral metronidazole was administered as fi rst-line therapy 
for CDI in 34 (49.2%) cases with mild/moderate forms of the 
disease (Table 3). This treatment proved effi  cacious in 27 
(79.4%) of 34 cases, resulting in cure in 41.9% of patients 
with CDI. Failure of metronidazole therapy was reported 
both in hospital-acquired infections (4/21 cases) and com-
munity-acquired infections (3/13 cases). More than 70% of 
all patients in which metronidazole was not effi  cacious had 
comorbidities, as compared with 22.2% of patients where 
metronidazole was effi  cacious.
For the treatment of the fi rst episode in mild/moderate 
forms of CDI, vancomycin was effi  cacious in all 33 cases (in 
25 cases it was used as fi rst-line therapy, and in eight cases 
as second-line therapy after metronidazole treatment fail-
ure), proving to be more effi  cacious than metronidazole. In 
severe forms, the combination of intravenous metronida-
zole and oral vancomycin was used. This approach cured all 
6 patients. Three patients had associated severe digestive 
disease, i.e. Hirschsprung’s disease or infl ammatory bowel 
disease. Oral vancomycin was successfully administered for 
the fi rst recurrence. In three cases with a second recurrence, 
rifaximin was the chosen therapy. Consecutively, no recur-
rences were reported.
DISCUSSION 
Our study showed a signifi cant increase, more than 4-fold, of 
CDI cases diagnosed between 2010 and 2015, as compared 
to previous years 2005-2009. This increase in CDI incidence is 
consistent with similar results reported from European stud-
ies (13-15). At the same time, the higher number of confi rmed 
cases may be a consequence of recent improvements in di-
agnostic technique; namely, more cases were tested for Clos-
tridium diffi  cile and tests for both toxins were used. The in-
crease in the incidence observed in 2014 may also be attrib-
uted to the fact that the diagnosis could be readily established 
with the tests available in our hospital.
The majority of study patients (50.7%) were children aged 
one to four years. In a recently published study, Zilberberg 
et al. analyzed CDI among hospitalized children in the Unit-
ed States between 1997 and 2006, and observed that the 
highest incidence of CDI was reported in the 1- to 4-year 
age group (4). We report the peak incidence between one 
and two years of age (41.1% of cases), the same as Pai et al., 
who have published an analysis of pediatric CDI cases diag-
nosed in a UK tertiary hospital (16). CDI was also diagnosed 
in infants: 15% in our study, a small percentage compared 
to 26% in the US report (3). The experts point to the fact that 
in this age group, the presence of Clostridium diffi  cile in stool 
TABLE 1. Characteristics of patients with Clostridium diffi  cile infection 
(CDI)
Median age (months) 28
Sex M/F (n) 31/42
Mild/moderate forms (n, %) 67 (91.7%)
Severe forms (n, %) 6 (8.3%)
Community-acquired CDI (n) 28




Hirschsprung’s disease (n) 5
Infl ammatory bowel disease 10
Ulcerative colitis (n) 8
Crohn’s disease (n) 1
Infl ammatory bowel disease, type unclassifi ed (n) 1
Cystic fi brosis 1
Intractable diarrhea 1
Immunodefi ciencies (n2=6)
Ig A defi ciency (n) 3
Transient hypogammaglobulinemia of infancy (n) 2
Secondary immunodefi ciency (n) 1
Others (n3=16)
• Celiac disease 3
• Cow’s milk allergy (n) 10
• Multiple food allergies (n) 3






Mean age (months) 34.6 43.9
Female (n) 16 3
Male (n) 11 4
Community-acquired CDI (n, %) 10 (37) 3 (42.8)
Hospital-acquired CDI (n, %) 17 (63) 4 (57.2)
Comorbidities (n, %) 6 (22.2) 5 (71.4)
CDI = Clostridium diffi  cile infection
68
LESANU G ET AL. CLOSTRIDIUM DIFFICILE INFECTION IN ROMANIAN CHILDREN. PAEDIATR CROAT. 2017;61:65-70
is not always pathologic, as infants may sometimes exhibit 
asymptomatic carriage.
Most of our patients had mild to moderate forms of CDI, but 
six patients had a severe form of the disease; one case with 
pseudomembranous colitis was admitted to the Intensive 
Care Unit and required complex therapeutic approach.
In recent years, an increasing number of studies reporting 
increasing incidence of community-acquired CDI have 
been published. For instance, a population-based study of 
CDI in pediatric residents (aged 0-18 years) of Olmsted 
County, Minnesota, from 1991 through 2009, demonstrated 
that the majority of cases (75%) were community-acquired, 
and the incidence of community-acquired CDI increased 
10.5-fold (17). In our study, 38.3% of patients had communi-
ty-acquired CDI.
A quarter of patients had associated gastrointestinal comor-
bidities, as patients were recruited among those admitted 
to Gastroenterology Department. It is interesting to note 
that the most frequently associated pathology was infl am-
matory bowel disease and cow’s milk allergy (13.7% both); 
similar fi ndings have been reported by Pai et al. (16).
In our study, we had recurrent episodes in only 24.2% of 
cases, which is a small percentage compared to other pedi-
atric studies (18). In adults, severe underlying disease has 
been suggested to be a risk factor for CDI recurrence (19). In 
our study, 17 of 73 (23.3%) patients had severe underlying 
comorbidities (Hirschsprung’s disease, infl ammatory bowel 
disease, cystic fi brosis or intractable diarrhea).
Half of the patients (49.2%) received oral metronidazole as 
fi rst-line treatment for mild to moderate CDI, according to 
the recommendation recently formulated by the American 
Academy of Pediatrics and sustained by several studies (16, 
20-22). This antibiotic is considered effi  cacious and relative-
ly inexpensive. Metronidazole is highly absorbed, with low 
fecal concentration levels in patients with diarrhea. A few 
recent reports show increased failure rates (23-26), but in 
our study it proved ineffi  cient in only 20.6% of cases. In a 
recent review, Vardakas et al. analyzed studies regarding CDI 
treatment in adults and found that treatment failure was 
22.4% with metronidazole (27).
The hospital-acquired infection was not a risk factor for met-
ronidazole treatment failure. A high percentage of patients 
for which metronidazole treatment proved ineffi  cient had 
diff erent associated comorbidities (Hirschsprung’s disease 
and infl ammatory bowel disease), as opposed to patients in 
which metronidazole treatment was effi  cacious (71.4% vs. 
22.2%). This diff erence was not statistically signifi cant be-
cause of the small number of patients enrolled, but is sug-
gestive of the fact that comorbidities might represent risk 
factors for metronidazole treatment failure. A recent retro-
spective study that evaluated CDI treatment in adults iden-
tifi ed diabetes mellitus and sepsis as risk factors for metroni-
dazole treatment failure in CDI (25).
Vancomycin is highly effi  cacious, is not absorbed, and 
achieves high fecal concentrations. It proved effi  cacious in 
all mild/moderate cases in the fi rst episode, regardless of 
whether it was initial treatment or treatment of an episode 
ineff ectively treated initially with metronidazole. Compar-
ing our results with the study by Vardakas et al., who found 
the rate of treatment failure to be 14.2% with vancomycin 
(27)], we found this antibiotic treatment to be more effi  -
cient.
Although oral vancomycin proved more effi  cacious than 
metronidazole for mild/moderate forms of CDI, we found 
no statistically signifi cant diff erence for initial cure, observa-
tion concordant with the review by Dreconja et al. that eval-
uated CDI treatment in adults (28).
All severe cases responded well to the combination of intra-
venous metronidazole and oral vancomycin, although we 
had fi ve cases with severe comorbidities and one case that 
developed a severe form of pseudomembranous colitis. Ac-
cordingly, we consider that this antibiotic combination 
should be the recommended treatment for severe CDI in 
children.
Patients with the fi rst recurrence received vancomycin, 
which proved effi  cacious in all cases. A second recurrence 
occurred in four patients; they received rifaximin, which 
proved eff ective. Rifaximin is a rifamycin-based non-syste-
mic antibiotic and data regarding its use in CDI treatment 
come from adult studies. These showed it to be useful for 
mild/moderate CDI cases that are resistant to metronidazo-
le or vancomycin (29, 30) and can be considered as an opti-
onal treatment for recurrences (31). Randomized trials are 
needed to confi rm these fi ndings in children.
Our study had some limitations, i.e. it was a retrospective 
study in a limited number of cases and presents the experi-
ence of a single pediatrics department. Nevertheless, it con-
tains Romanian data on CDI and treatment outcome in chil-
dren; to date, very few data have been reported on the issue 
from our geographical area.
CONCLUSIONS
This was the fi rst Romanian study assessing the characteris-
tics and antibiotic treatment of CDI in children. We report an 
increasing incidence of CDI in children. The highest inci-
dence of CDI was found in the one to four years age group. 
One quarter of patients had associated comorbidities, the 
most frequent being infl ammatory bowel disease and cow’s 
milk allergy. In our country, the rate of failure of metronida-
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zole therapy for CDI treatment was found to be low, there-
fore we consider it may still be safely recommended for the 
fi rst mild/moderate episode of CDI in children. Vancomycin 
proved effi  cacious in all cases, regardless of whether it was 
the fi rst episode or recurrence of CDI, and we consider it to 
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S A Ž E T A K
Infekcija bakterijom Clostridium diffi  cile u djece: 
značajke i liječenje – istraživanje u jednom centru 
u Rumunjskoj
Gabriela Lesanu, Raluca Maria Vlad, Cristina Adriana Becheanu, Mirela Ionela Stocklosa, Irina Dijmarescu, 
Alexandra Coroleuca, Daniela Lemeni, Ioana Sabina Macovei, Irina Nistor, Daniela Pacurar
Incidencija infekcije bakterijom Clostridium diffi  cile (CDI) u djece u progresivnom je porastu. U ovom istraživanju procijenjene su 
značajke i antibakterijska terapija CDI na jednom odjelu pedijatrijske gastroenterologije u Rumunjskoj. Provedeno je retrospektivno 
istraživanje u kojem su analizirani slučajevi CDI utvrđeni na osnovi imunoloških testova na toksine Clostridium diffi  cile u stolici od 1. 
siječnja 2005. do 31. prosinca 2015. godine. U 73 bolesnika dijagnosticirano je 89 epizoda CDI. Zabilježena je rastuća incidencija CDI 
s najvišom stopom 2014. godine sa 6,9 slučajeva na 1000 bolesnika. CDI stečena u zajednici utvrđena je u gotovo 40% bolesnika. 
Najčešće pridružene istodobne bolesti bile su upalna crijevna bolest i alergija na kravlje mlijeko. Postotak ponovljenih epizoda bio je 
nizak (24,2%). Metronidazol kao terapija prvog izbora davao se u 49,2% blažih/umjerenih slučajeva i pokazao se učinkovitim u 
79,4% njih. Istodobno prisutne bolesti zabilježene su u više od 70% bolesnika u kojih metronidazol nije bio učinkovit u usporedbi s 
22,2% bolesnika kod kojih je metronidazol bio učinkovit. Alternativna terapija bio je vankomicin koji je izliječio bolest u svim slučaje-
vima. U teškim oblicima bolesti kombinacija intravenskog metronidazola i peroralnog vankomicina pokazala se učinkovitim rješe-
njem. Peroralni vankomicin bio je učinkovit u liječenju prve ponovljene epizode bolesti. Ukazuje se na rastuću incidenciju CDI kod 
rumunjske djece. Stopa neupješnog liječenja metronidazolom bila je niska pa se ovaj lijek može sa sigurnošću preporučiti za liječenje 
prve epizode blaže/umjerene CDI. Vankomicin se pokazao učinkovitim u svim slučajevima bez obzira na to radi li se o prvoj ili ponov-
ljenoj epizodi bolesti i može se učinkovito primijeniti kao terapija prvog izbora.
Ključne riječi: Clostridium diffi  cile; antibakterijska terapija; djeca
